Rock Creek Advisors (the “Sale Agent”) is contacting you regarding Exeevo, Inc. (the “Company” or “Exeevo”). In parallel with other initiatives, we are helping the company evaluate strategic alternatives, which may include, but are not limited to an asset sale of the operating business, all associated IP, trademarks, partnerships and licenses. Exeevo…

Rock Creek Advisors is contacting you regarding the sale of the SY-2101 program of Syros Pharmaceuticals, Inc. (the “Company” or “Syros”). Assets for sale include: Phase 3-ready clinical data package, Final FDA/EMA-aligned Phase 3 protocol along with draft briefing book and protocol for a streamlined Phase 3 approach, An engaged global network…